NCT06107023Completed
Action Observation Training With 3D Virtual Reality in Patients With Multiple Sclerosis
Investigation of the Effect of Action Observation Training With 3D Virtual Reality on Upper Extremity Functions in Patients With Multiple Sclerosis With Attacks
Source: ClinicalTrials.gov · Last updated 28 Jan 2026
Brief summary (registry, in English)
Multiple sclerosis is a chronic, autoimmune and inflammatory disease of the Central Nervous System characterized by neuronal demyelination and axonal degeneration. Upper extremity problems are present in MS patients from an early stage, affecting the performance of the individual and leading to a decrease in activity of daily living ability in proportion to the extent of the problem. Action Observation Training is currently being examined as one of the methods used for the improvement of motor disorders and has been shown in the literature to be effective on different functions in neurological diseases. The aim of this study was to investigate the effects of action observation training with 3D virtual reality on upper extremity functions, fatigue, cognitive functions, activities of daily living and quality of life in MS patients. Hypothesis 1: Action observation training with 3D virtual reality has an effect on upper extremity functions in MS patients. Hypothesis 2: Action observation training with 3D virtual reality has an effect on cognitive function in MS patients. Hypothesis 3: Action observation training with 3D virtual reality has an effect on fatigue in MS patients. Hypothesis 4: Action observation training with 3D virtual reality has an effect on activities of daily living in MS patients. Hypothesis 5: Action observation training with 3D virtual reality has an effect on quality of life in MS patients.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 18 Oct 2023
- Start date
- 15 Nov 2023
- Primary completion date
- 2 Feb 2025
- Lead sponsor
- Abant Izzet Baysal University
- Diseases
- Multiple sclerosis
- NCT number
- NCT06107023
What you commit to
- Study type: Interventional
- Participants enrolled: 32
- From 15 Nov 2023 to the primary completion date, 2 Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receiving botulinum toxin treatment in the last 6 months
Other illness
- diagnosed with neurological (except MS), cardiopulmonary, metabolic or musculoskeletal disease that would prevent treatment and evaluation
- visual impairment uncorrected by optical devices
- inability to adapt to treatment based on 3D immersive virtual reality (e.g. with cognitive impairment, communication problems, psychological problems or vestibular system problems)
Who the study is looking for
- \< 2 years MS diagnosis according to McDonald criteria
- between 3.5 and 6 the EDSS
- Nine Hole Peg Test \> 30s for at least one upper extremity
- no change in medication in the last 6 months
- having MS disease with ongoing attacks
- \>2 Modified Ashworth Scale in the upper extremities
- MOCA\>25
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Izzet Baysal University Coordinator of this site? Confirm its status | Bolu | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.